News

Soleno signals $500M cash war chest and robust Vykat XR launch trajectory while advancing EU expansion

Discover key insights from Soleno Therapeutics' Q2 2025 earnings call, highlighting Vykat XR's strong launch, revenue growth, EU expansion efforts & ...

Arko outlines $70M–$80M Q3 adjusted EBITDA guidance while advancing dealerization and store remodels

Discover key insights from Arko Corp's Q2 2025 earnings call. Explore dealerization progress, margin growth, and strategic transformations.